Healthcare industry executive Robert L. Gershon to join as Chief Executive Officer and Board Member, bringing 30 years of commercial leadership...
Executive Leadership Transition to Support New Phase of Growth
read more
Search Results
Mauna Kea Technologies Announces First Published Report of Live “Tele-Cellvizio®” Utilization In Vivo between Surgeons and Remote Pathologists
Results of breakthrough PERSEE trial involving live transmission and robotized use of Cellvizio confocal miniprobe published online in Surgical...
Results from Large U.S. Prospective Multi-Center Clinical Trial on Detection of Barrett’s Esophagus with Cellvizio®
Results of the 8 non academic center trial publish online in Surgical Endoscopy, the official journal of SAGES, the Society of American...
Join the Mauna Kea Technologies 2018 Half Year Results
Sacha Loiseau, Founder, CEO and Christophe Lamboeuf, CFO will host an English-language conference call at 7:15 PM CEDT, Paris time (1:15 PM EDT, New...
nCLE Solution for Applications in Lung Cancer and Other Pulmonary Diseases during ERS 2018
The availability of the needle-based Cellvizio platform, now bearing CE mark, could be a game changer for the management of patients with certain...
Mauna Kea Technologies Reports Second Quarter and First Half 2018 Sales
Download the full press release here
Positive Results from Mayo Clinic Sponsored Prospective Multi-center Trial in Lung Transplant Patients
Cellvizio’s optical biopsy could become a safe and effective alternative to invasive biopsies in transplanted patients Mauna Kea...
20 Presentations Highlighting Cellvizio’s® Clinical Value in Evaluating IBDs and Pancreatic Cysts at DDW 2018
Twenty accepted abstracts demonstrate growing clinical adoption and recognition of Cellvizio as a necessary tool for real-time optical biopsy in...
Mauna Kea Technologies obtains first ever FDA clearance for applications of Cellvizio® Confocal Laser Endomicroscopy in Neurosurgery
Pivotal regulatory milestone in high stakes applications Cellvizio first-to-market in key neurosurgery field Provides unique response to unmet needs...
Cellvizio® Demonstrates Superior Identification of Patients at Risk for Esophageal Cancer Compared to Current Diagnostic Standard
Results from new clinical study that enrolled 172 patients at 8 non-academic centers in the United-States was presented at 2018 World Congress of...
Appointment of Christophe Lamboeuf to the position of Chief Financial Officer
Mauna Kea Technologies has appointed Christophe Lamboeuf to the position of Chief Financial Officer. Christophe Lamboeuf succeeds Olivier...
In Vivo Confocal Laser Endomicroscopy with Cellvizio® allows the discovery of a previously unknown human structure, the interstitium
According to the publication in Nature Group’s Scientific Reports, this discovery may have significance in cancer metastasis and other...